David McAvoy
General Counsel at TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Net worth: 15 078 $ as of 30/04/2024
David McAvoy active positions
Companies | Position | Start | End |
---|---|---|---|
TEVA PHARMACEUTICAL INDUSTRIES LIMITED | General Counsel | 01/03/2024 | - |
Villages of Indiana | Director/Board Member | - | - |
Career history of David McAvoy
Former positions of David McAvoy
Companies | Position | Start | End |
---|---|---|---|
FRESH TRACKS THERAPEUTICS, INC. | Compliance Officer | 01/01/2019 | 01/09/2023 |
General Counsel | 01/01/2019 | 01/09/2023 | |
ELI LILLY AND COMPANY | Corporate Officer/Principal | - | - |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Compliance Officer | 31/08/2019 | - |
General Counsel | 31/08/2019 | - | |
Brickell Subsidiary, Inc.
Brickell Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology Brickell Subsidiary, Inc. operates as a clinical-stage pharmaceutical company. It focuses on the development of differentiated, innovative drug therapies for the treatment of skin diseases. The firm specializes in Hyperhidrosis, Cutaneous T-Cell Lymphoma and Psoriasis areas. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in November 2009 and is headquartered in Boulder, CO. | Compliance Officer | 01/01/2019 | - |
General Counsel | 01/01/2019 | - | |
ENDOCYTE, INC. | Compliance Officer | 01/01/2018 | - |
General Counsel | 01/01/2018 | - |
Training of David McAvoy
Indiana University | Graduate Degree |
University of Notre Dame | Undergraduate Degree |
Statistics
International
United States | 9 |
Israel | 2 |
Operational
General Counsel | 5 |
Compliance Officer | 4 |
Graduate Degree | 1 |
Sectoral
Health Technology | 7 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 3 |
---|---|
FRESH TRACKS THERAPEUTICS, INC. | Health Technology |
ELI LILLY AND COMPANY | Health Technology |
TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Health Technology |
Private companies | 4 |
---|---|
Endocyte, Inc.
Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN. | Health Technology |
Villages of Indiana | |
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
Brickell Subsidiary, Inc.
Brickell Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology Brickell Subsidiary, Inc. operates as a clinical-stage pharmaceutical company. It focuses on the development of differentiated, innovative drug therapies for the treatment of skin diseases. The firm specializes in Hyperhidrosis, Cutaneous T-Cell Lymphoma and Psoriasis areas. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in November 2009 and is headquartered in Boulder, CO. | Health Technology |
- Stock Market
- Insiders
- David McAvoy
- Experience